Skip to content

Tazarotene

    Brands

    DEA Class; Rx

    Common Brand Names; Avage, Tazorac, Fabior, Arazlo

    • Acne Agents, Topical; 
    • Antipsoriatics, Topical; 
    • Retinoid-like Agents, Topical

    Retinoid prodrug
    Used for psoriasis, acne, and facial wrinkles and pigmentation changes primarily due to photoaging
    Contraindicated in pregnancy; females of childbearing potential should use adequate birth control

    Indicated for the treatment of  for the treatment of plaque psoriasis.

    For the topical treatment of acne vulgaris.
    For adjunctive treatment of fine facial wrinkles and facial mottled hyperpigmentation (i.e., ‘liver spots’) and hypopigmentation associated with photoaging.

    Pregnancy

    Hypersensitivity

    • Scaling (51%)
    • Erythema (34-49%)
    • Desquamation (40%)
    • Burning/stinging (22-30%)
    • Itching (29%)
    • Dry skin (15%)
    • Skin irritation (10%)
    • Pruritus (10%)
    • Irritant contact dermatitis (8%)
    • Stinging (3%)
    • Rash (3%)
    • Cheilitis (1%)

    Propellant in foam is flammable; avoid fire, flame, and/or smoking during and immediately following application

    There are no adequate and well-controlled studies with use in pregnant women

    Contraindicated in females who are or may become pregnant

    Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed child from therapy or from the underlying maternal condition

    Adults

    1 application per day topically.

    Geriatric

    1 application per day topically.

    Adolescents

    17 years: 1 application per day topically.
    less than 17 years: 1 application per day topically; safety and efficacy of Avage 0.1% cream have not been established.

    Children

    12 years: 1 application per day topically; safety and efficacy of Avage 0.1% cream have not been established.
    9 to 12 years: 1 application per day topically for Arazlo 0.045% lotion; safety and efficacy of other formulations have not been established
    less than 9 years: Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Tazarotene

    cream, topical

    • 0.1% (Avage, Tazorac, generic)

    gel, topical

    • 0.05% (Tazorac, generic)
    • 0.1% (Tazorac, generic)

    foam, topical

    • 0.1% (Fabior)

    lotion, topical

    • 0.045% (Arazlo)